The Impact of Unlicensed and Off-Label Drug Use on Adverse Drug Reactions in Paediatric Patients
- 1 January 2004
- journal article
- Published by Springer Nature in Drug Safety
- Vol. 27 (13), 1059-1067
- https://doi.org/10.2165/00002018-200427130-00006
Abstract
Background and objective: Many drugs that are used to treat children are either not licensed for use in paediatric patients (unlicensed) or prescribed outside the terms of the product licence (off label). The incidence of adverse drug reactions (ADRs) associated with the use of such drugs is yet to be established. This study investigates, for the first time in a German patient population, the impact of unlicensed and off-label drug use on ADRs in paediatric patients. Patients and methods: An 8-month prospective pharmacoepidemiological cohort-based survey was conducted on a ten-bed paediatric isolation ward at the University Hospital Erlangen-Nüremberg, Germany. All patients were intensively monitored for ADRs by a pharmacoepidemiological team. ADRs were characterised according to international classification methods. All drug prescriptions were evaluated retrospectively as to unlicensed or off-label use on the basis of the product information. Results: A total of 178 patients were included in the study and 740 drug prescriptions were given to 156 patients (median three prescriptions per patient). In 198 cases (27.7% of all prescriptions) drugs were used in either an unlicensed (n = 3) or off-label (n = 195) manner. A total of 46 ADRs were observed in 31 patients (17.4%). Patients receiving at least one unlicensed or off-label drug prescription during hospitalisation (n = 92) experienced an ADR significantly more frequently (n = 26 patients) than patients receiving only licensed drugs (n = 64 vs 5 patients). ADRs were associated with 29 (5.6%) of the 517 licensed drug prescriptions and with 12 (6.1%) of the 198 unlicensed or off-label drug prescriptions. The majority of ADRs caused by unlicensed and off-label drug use were recognised by the attending physician. However, statistical analysis revealed no significant difference in the number of licensed and unlicensed/off-label drug prescriptions causing ADRs. Conclusion: This study demonstrated that at a paediatric isolation ward the incidence of ADRs caused by unlicensed or off-label drug use was not significantly more than that caused by the licensed drug use. However, patients treated with unlicensed or off-label drugs were shown to possess a significantly increased risk for developing ADRs.Keywords
This publication has 31 references indexed in Scilit:
- Adverse drug reactions and off-label drug use in paediatric outpatientsBritish Journal of Clinical Pharmacology, 2002
- Unlicensed and Off-Label Drug Use in ChildrenDrug Safety, 2002
- Incidence of adverse drug reactions in paediatric in/out‐patients: a systematic review and meta‐analysis of prospective studiesBritish Journal of Clinical Pharmacology, 2001
- Off label and unlicensed drug use among French office based paediatriciansArchives of Disease in Childhood, 2000
- Unlicensed and off label prescribing of drugs in general practiceArchives of Disease in Childhood, 2000
- Incidence and Costs of Adverse Drug Reactions During HospitalisationDrug Safety, 2000
- Adverse drug reactions to unlicensed and off‐label drugs on paediatric wards: a prospective studyActa Paediatrica, 1999
- Unlicensed and off label drug use in neonates CommentaryArchives of Disease in Childhood: Fetal & Neonatal, 1999
- Computerized surveillance of adverse drug reactions in hospital: pilot studyBritish Journal of Clinical Pharmacology, 1998
- Potential Identifiability and Preventability of Adverse Events Using Information SystemsJournal of the American Medical Informatics Association, 1994